drugset / Trial / NCT00002224

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

NCT00002224

Phase 3 Completed 120 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

Didanosine is an effective anti-HIV drug, but it can cause stomach upset. This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach more easily and hopefully will prevent stomach upset. The purpose of this study is to compare the effectiveness of ddI EC versus the standard form of ddI. Both forms of ddI will be given with stavudine (d4T) plus nelfinavir (NLF).

Timeline

Start
1999-03
Primary completion
1999-03
Completion
1999-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Didanosine Small molecule Oral
Background Nelfinavir Other / unclassified
Background Stavudine Other / unclassified